

Publikationen mit Krebsregisterdaten 2019-2023 (1-132)

2019

1. Arndt V, Kraywinkel K, Zeissig SR. Beiträge der Epidemiologie bei der Primärprävention von Krebserkrankungen. *Der Onkologe*. 2019;25(1):7-13.
2. Bannon F, Di Carlo V, Harewood R, Engholm G, Ferretti S, Johnson CJ, et al. Survival trends for primary liver cancer, 1995–2009: analysis of individual data for 578,740 patients from 187 population-based registries in 36 countries (CONCORD-2). *Annals of Cancer Epidemiology*. 2019;3.
3. Holleczeck B, Stegmaier C, Radosa JC, Solomayer EF, Brenner H. Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis - results from a registry-based study from Germany. *BMC Cancer*. 2019;19(1):520.
4. Hübner J, Hübner F, Terheyden P, Katalinic A. Trendwende bei der Hautkrebsmortalität. Eine Analyse der Entwicklung in Deutschland von 1998 bis 2017. *Hautarzt*. 2019;70(12):989-92.
5. Jaehn P, Kaucher S, Pikalova LV, Mazeina S, Kajüter H, Becher H, et al. A cross-national perspective of migration and cancer: incidence of five major cancer types among resettlers from the former Soviet Union in Germany and ethnic Germans in Russia. *BMC Cancer*. 2019;19(1):869.
6. Kraywinkel K. Epidemiologie der myeloproliferativen Neoplasien und myelodysplastischen Syndrome in Deutschland. *Der Onkologe*. 2019;25(11):948-56.
7. March S, Andrich S, Drepper J, Horenkamp-Sonntag D, Icks A, Ihle P, et al. Gute Praxis Datenlinkage (GPD). *Gesundheitswesen*. 2019;81(08/09):636-50.
8. Medenwald D, Vordermark D, Dietzel CT. Early Mortality of Prostatectomy vs. Radiotherapy as a Primary Treatment for Prostate Cancer: A Population-Based Study From the United States and East Germany. *Front Oncol*. 2019;9:1451.
9. Pölcher M, Rottmann M, Brugger S, Mahner S, Dannecker C, Kiechle M, et al. Lymph node dissection in endometrial cancer and clinical outcome: A population-based study in 5546 patients. *Gynecol Oncol*. 2019;154(1):65-71.
10. Prange A, Bokhof B, Polzer P, Tio J, Radke I, Heidinger O, et al. Higher Detection Rates of Biologically Aggressive Breast Cancers in Mammography Screening than in the Biennial Interval. *Rofo*. 2019;191(2):130-6.
11. Radespiel-Tröger M, Voigtländer S, Meyer M, Müller-Nordhorn J, Behringer J, Schöfl C, Holleederer A. Assoziation zwischen Häufigkeit der Sonographie und Prävalenz bösartiger Neubildungen der Schilddrüse bei Versicherten der AOK in Bayern. *Der Onkologe*. 2019;25(7):559-68.
12. Rudolph C, Petersen GS, Pritzkeleit R, Storm H, Katalinic A. The acceptance and applicability of a patient-reported experience measurement tool in oncological care: a descriptive feasibility study in northern Germany. *BMC Health Serv Res*. 2019;19(1):786.
13. Semjonow A, Hense HW, Schlößler K, Simbrich A, Borowski M, Bothe C, et al. Development and Prospective Randomized Evaluation of a Decision Aid for Prostate-specific Antigen-based Early Detection of Prostate Cancer in Men Aged Between 55 and 69Yr: The PSAInForm Trial. *Eur Urol*. 2019;76(1):1-3.
14. Stang A, Khil L, Kajüter H, Pandeya N, Schmults CD, Ruiz ES, et al. Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents. *Journal of the European Academy of Dermatology and Venereology*. 2019;33(S8):6-10.
15. Wienecke A, Kraywinkel K. Epidemiologie von Kopf-Hals-Tumoren in Deutschland. *Der Onkologe*. 2019;25(3):190-200.
16. Wittekandt C, Wagner S, Bushnak A, Prigge ES, von Knebel Doeberitz M, Würdemann N, et al. Increasing Incidence rates of Oropharyngeal Squamous Cell Carcinoma in Germany and Significance of Disease Burden Attributed to Human Papillomavirus. *Cancer Prev Res (Phila)*. 2019;12(6):375-82.

17. Zeissig SR. Zertifizierung und Krebsregistrierung nach dem KFRG: Zwei Welten? Forum. 2019;34(3):256-8.

2020

18. Arndt V, Holleczeck B, Kajüter H, Luttmann S, Nennecke A, Zeissig SR, et al. Data from Population-based Cancer Registration for Secondary Data Analysis: Methodological Challenges and Perspectives. *Gesundheitswesen*. 2020;82(S 01):S62-s71.
19. Barnes B. Primärprävention von Plattenepithelkarzinomen des Ösophagus und des Anus. *Der Onkologe*. 2020;26(4):367-70.
20. Becker C, Graf N, Grabow D, Creutzig U, Reinhardt D, Weyer-Elberich V, et al. Early deaths from childhood cancer in Germany 1980-2016. *Cancer Epidemiol*. 2020;65:101669.
21. Brunssen A, Jansen L, Eisemann N, Waldmann A, Weberpals J, Kraywinkel K, et al. Long-term relative survival from melanoma in Germany 1997-2013. *Melanoma Res*. 2020;30(4):386-95.
22. Buttman-Schweiger N, Kraywinkel K. Epidemiologie von Krebserkrankungen des Anus und Analkanals in Deutschland. *Der Onkologe*. 2020;26(4):306-10.
23. Dittberner A, Friedl B, Wittig A, Buentzel J, Kaftan H, Boeger D, et al. Gender Disparities in Epidemiology, Treatment, and Outcome for Head and Neck Cancer in Germany: A Population-Based Long-Term Analysis from 1996 to 2016 of the Thuringian Cancer Registry. *Cancers (Basel)*. 2020;12(11).
24. Doege D, Thong MSY, Koch-Gallenkamp L, Jansen L, Bertram H, Eberle A, et al. Age-specific prevalence and determinants of depression in long-term breast cancer survivors compared to female population controls. *Cancer Med*. 2020;9(22):8713-21.
25. Emrich K, Kraywinkel K. Epidemiologie des Rektumkarzinoms in Deutschland. *Der Onkologe*. 2020;26(12):1085-94.
26. Engel J, Schubert-Fritschle G, Emeny R, Hölzel D. Breast cancer: are long-term and intermittent endocrine therapies equally effective? *J Cancer Res Clin Oncol*. 2020;146(8):2041-9.
27. Ernst M, Brähler E, Wild PS, Jünger C, Faber J, Schneider A, Beutel ME. Risk factors for suicidal ideation in a large, registry-based sample of adult long-term childhood cancer survivors. *J Affect Disord*. 2020;265:351-6.
28. Evers C, Ostheimer C, Sieker F, Vordermark D, Medenwald D. Benefit from surgery with additional radiotherapy in N1 head and neck cancer at the time of IMRT: A population-based study on recent developments. *PLOS ONE*. 2020;15(2):e0229266.
29. Finke I, Behrens G, Schwettmann L, Gerken M, Pritzkeleit R, Holleczeck B, et al. Socioeconomic differences and lung cancer survival in Germany: Investigation based on population-based clinical cancer registration. *Lung Cancer*. 2020;142:1-8.
30. Fröhling S, Arndt V. Versorgung von Krebspatienten: Corona-Effekt in der Onkologie. *Dtsch Arztebl*. 2020;117(46):A-2234/B-1893.
31. Gredner T, Niedermaier T, Brenner H, Mons U. Impact of Tobacco Control Policies on Smoking-Related Cancer Incidence in Germany 2020 to 2050-A Simulation Study. *Cancer Epidemiol Biomarkers Prev*. 2020;29(7):1413-22.
32. Grundmann N, Meisinger C, Trepel M, Müller-Nordhorn J, Schenkirsch G, Linseisen J. Trends in cancer incidence and survival in the Augsburg study region-results from the Augsburg cancer registry. *BMJ Open*. 2020;10(8):e036176.
33. Guo F, Chen C, Schöttker B, Holleczeck B, Hoffmeister M, Brenner H. Changes in colorectal cancer screening use after introduction of alternative screening offer in Germany: Prospective cohort study. *Int J Cancer*. 2020;146(9):2423-32.
34. Hager T, Kraywinkel K, Szarvas T, Hadaschik B, Schmid KW, Reis H. Urachal Cancer in Germany and the USA: An RKI/SEER Population-Based Comparison Study. *Urol Int*. 2020;104(9-10):803-9.
35. Hammersen F, Pursche T, Fischer D, Katalinic A, Waldmann A. Use of Complementary and Alternative Medicine among Young Patients with Breast Cancer. *Breast Care (Basel)*. 2020;15(2):163-70.

36. Heisser T, Guo F, Niedermaier T, Holleczeck B, Hoffmeister M, Brenner H. Low Risk of Advanced Neoplasms for up to 20 Years After Negative Colonoscopy Result: Potential for Personalized Follow-up Screening Intervals. *Gastroenterology*. 2020;159(6):2235-7.e4.
37. Hellmund P, Schmitt J, Roessler M, Meier F, Schoffer O. Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000-2016. *Cancers (Basel)*. 2020;12(9).
38. Heppt MV, Leiter U, Steeb T, Amaral T, Bauer A, Becker JC, et al. S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Kurzfassung, Teil 1: Diagnostik, Interventionen bei aktinischen Keratosen, Versorgungsstrukturen und Qualitätsindikatoren. *JDDG: Journal der Deutschen Dermatologischen Gesellschaft*. 2020;18(3):275-94.
39. Hermann S, Jansen L, Barnes B, Kraywinkel K. Epidemiologie des Magenkarzinoms in Deutschland. *Der Onkologe*. 2020;26(10):887-97.
40. Hertrampf K, Pritzkeleit R, Baumann E, Wiltfang J, Wenz HJ, Waldmann A. Oral cancer awareness campaign in Northern Germany: first positive trends in incidence and tumour stages. *J Cancer Res Clin Oncol*. 2020;146(10):2489-96.
41. Holleczeck B, Schöttker B, Brenner H. Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: Results from the prospective population-based ESTHER cohort study. *Int J Cancer*. 2020;146(10):2773-83.
42. Hübner J, Katalinic A, Waldmann A, Kraywinkel K. Long-term Incidence and Mortality Trends for Breast Cancer in Germany. *Geburtshilfe Frauenheilkd*. 2020;80(6):611-8.
43. Jansen L, Behrens G, Finke I, Maier W, Gerken M, Pritzkeleit R, et al. Area-Based Socioeconomic Inequalities in Colorectal Cancer Survival in Germany: Investigation Based on Population-Based Clinical Cancer Registration. *Front Oncol*. 2020;10:857.
44. Jansen L, Hermann S, Bergbold S, Holleczeck B, Heil J, Kraywinkel K, Arndt V. Überleben nach primär metastasiertem Brustkrebs. *Der Onkologe*. 2020;26(6):487-96.
45. Jansen L, Holleczeck B, Kraywinkel K, Weberpals J, Schröder CC, Eberle A, et al. Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States. *Cancers (Basel)*. 2020;12(9).
46. Jansen L, Schröder CC, Emrich K, Holleczeck B, Pritzkeleit R, Brenner H. Disclosing progress in cancer survival with less delay. *Int J Cancer*. 2020;147(3):838-46.
47. Katalinic A, Eisemann N, Kraywinkel K, Noftz MR, Hübner J. Breast cancer incidence and mortality before and after implementation of the German mammography screening program. *Int J Cancer*. 2020;147(3):709-18.
48. Kaucher S, Khil L, Kajüter H, Becher H, Reder M, Kolip P, et al. Breast cancer incidence and mammography screening among resettlers in Germany. *BMC Public Health*. 2020;20(1):417.
49. Khil L, Heidrich J, Wellmann I, Käb-Sanyal V, Weigel S, Heindel W, et al. Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: a prospective register-based study. *BMC Cancer*. 2020;20(1):174.
50. Konrad C, Lossnitzer N, Boehlen FH, Haefeli WE, Holleczeck B, Brenner H, et al. Coping resources of heart failure patients - a comparison with cancer patients and individuals having no chronic condition results from the esther study. *Heart Lung*. 2020;49(6):829-35.
51. Kraywinkel K, Buttman-Schweiger N. Epidemiologie bösartiger Tumoren der Speiseröhre in Deutschland unter Berücksichtigung der histologischen Typen. *Der Onkologe*. 2020;26(4):311-6.
52. Kraywinkel K, Wienecke A. Inzidenz, Mortalität und Überleben von Krebserkrankungen in Deutschland. In: Schmoll H, editor. *Kompendium Internistische Onkologie: Springer Reference - Medicine*; 2020.
53. Lindblad A, Kaucher S, Jaehn P, Kajüter H, Holleczeck B, Lissner L, et al. The Incidence of Intestinal Gastric Cancer among Resettlers in Germany—Do Resettlers Remain at an Elevated Risk in Comparison to the General Population? *International Journal of Environmental Research and Public Health*. 2020;17(24):9215.

54. Medenwald D, Ferencz J, Vordermark D. Predictors of the regional variation of prostatectomy or radiotherapy: evidence from German cancer registries. *J Cancer Res Clin Oncol.* 2020;146(5):1197-204.
 55. Minicozzi P, Vicentini M, Innos K, Castro C, Guevara M, Stracci F, et al. Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study. *Eur J Surg Oncol.* 2020;46(6):1151-9.
 56. Nennecke A, Waldmann A, Hentschel S. Qualitätssicherung durch Versorgungstransparenz. *Hamburger Ärzteblatt.* 2020;02/2020:28-9.
 57. Nimptsch K, Jaeschke L, Chang-Claude J, Kaaks R, Katzke V, Michels KB, et al. Selbstberichtete Krebserkrankungen in der NAKO Gesundheitsstudie: Erfassungsmethoden und erste Ergebnisse. *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.* 2020;63(4):385-96.
 58. Prantl L, Gerken M, Zeman F, Leitzmann M, Koller M, Klinkhammer-Schalke M, et al. Incidence of Anaplastic Large Cell Lymphoma and Breast-Implant-Associated Lymphoma-An Analysis of a Certified Tumor Registry over 17 Years. *J Clin Med.* 2020;9(5).
 59. Sant M, Meneghini E, Bastos J, Rossi PG, Guevara M, Innos K, et al. Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study. *Breast Cancer Res Treat.* 2020;183(2):439-50.
 60. Scheidt-Nave C, Barnes B, Beyer A-K, Busch M, Hapke U, Heidemann C, et al. Versorgung von chronisch Kranken in Deutschland - Herausforderungen in Zeiten der COVID-19-Pandemie. *Journal of Health Monitoring.* 2020(S10):1--28.
 61. Schmidt ME, Hermann S, Arndt V, Steindorf K. Prevalence and severity of long-term physical, emotional, and cognitive fatigue across 15 different cancer entities. *Cancer Med.* 2020;9(21):8053-61.
 62. Sirri E, Kieschke J, Vohmann C, Katalinic A, Nennecke A, Rensing M, et al. Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population-based study. *Int J Cancer.* 2020;147(6):1548-58.
 63. Spanier G, Böttcher J, Gerken M, Fischer R, Roth G, Lehn P, et al. Prognostic value of perioperative red blood cell transfusion and anemia on survival and recurrence in oral squamous cell carcinoma. *Oral Oncol.* 2020;107:104773.
 64. Stang A, Kühling L, Khil L, Kajüter H, Schützendübel A, Mattauch V. Drop in Cancer Reporting by Pathologists in North Rhine-Westphalia, Germany, During the COVID-19 Lockdown. *Dtsch Arztebl Int.* 2020;117(51-52):886-7.
 65. Stang A, Wellmann I, Kajüter H, Trocchi P, Becker JC, Green AC, et al. Differences in site-specific incidence and relative survival of cutaneous and mucocutaneous genital squamous cell carcinoma in Germany, 2007-2015. *International Journal of Cancer.* 2020;147(10):2772-9.
 66. Stangl S, Haas K, Eichner FA, Grau A, Selig U, Ludwig T, et al. Development and proof-of-concept of a multicenter, patient-centered cancer registry for breast cancer patients with metastatic disease-the "Breast cancer care for patients with metastatic disease" (BRE-4-MED) registry. *Pilot Feasibility Stud.* 2020;6:11.
 67. Yu H, Raut JR, Schöttker B, Holleczer B, Zhang Y, Brenner H. Individual and joint contributions of genetic and methylation risk scores for enhancing lung cancer risk stratification: data from a population-based cohort in Germany. *Clin Epigenetics.* 2020;12(1):89.
 68. Zeissig SR, Arndt V, Kraywinkel K. Beiträge der Epidemiologie bei der Sekundärprävention von Krebserkrankungen. *Der Onkologe.* 2020;26(5):393-401.
- 2021**
69. Arndt V, Dahm S, Kraywinkel K. Krebsprävalenz in Deutschland 2017. *Der Onkologe.* 2021;27(8):717-23.
 70. Arndt V, Mehnert-Theuerkauf A, Singer S, Höffken K. Cancer Survivorship – Leben mit Krebs/Leben nach Krebs. *Der Onkologe.* 2021;27(8):714-6.

71. Bedir A, Abera SF, Efremov L, Hassan L, Vordermark D, Medenwald D. Socioeconomic disparities in head and neck cancer survival in Germany: a causal mediation analysis using population-based cancer registry data. *J Cancer Res Clin Oncol.* 2021;147(5):1325-34.
72. Bernhardt K, Neuser P, Kim-Wanner S-Z. Nierenzellkarzinom: Daten aus Hessen - Qualitätssicherung der onkologischen Versorgung durch das Hessische Krebsregister. *Hessisches Ärzteblatt.* 2021;6:384-5.
73. Calaminus G, Baust K, Berger C, Byrne J, Binder H, Casagrande L, et al. Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. *JMIR Res Protoc.* 2021;10(1):e21851.
74. Cardoso R, Guo F, Heisser T, Hackl M, Ihle P, De Schutter H, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. *Lancet Oncol.* 2021;22(7):1002-13.
75. Cardoso R, Zhu A, Guo F, Heisser T, Hoffmeister M, Brenner H. Incidence and Mortality of Proximal and Distal Colorectal Cancer in Germany—Trends in the Era of Screening Colonoscopy. *Dtsch Arztebl Int.* 2021;118(16):281-7.
76. Doege D, Thong MSY, Koch-Gallenkamp L, al. e. Depression und kognitive Funktionsfähigkeit bei Langzeit Brustkrebsüberlebenden im Vergleich zur Allgemeinbevölkerung - Ergebnisse einer bevölkerungsbezogenen Untersuchung 5-15 Jahre nach Diagnose. *Gynäkologische Praxis.* 2021;48(1):22-30.
77. Doege D, Thong MSY, Weißer L, Koch-Gallenkamp L, Jansen L, Bertram H, et al. Health-Related Quality of Life in Very Long-Term Cancer Survivors 14-24 Years Post-Diagnosis Compared to Population Controls: A Population-Based Study. *Cancers (Basel).* 2021;13(11).
78. Efremov L, Abera SF, Bedir A, Vordermark D, Medenwald D. Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries. *J Cancer Res Clin Oncol.* 2021;147(11):3381-90.
79. Emrich K, Kraywinkel K. Epidemiologie des kleinzelligen Lungenkarzinoms in Deutschland. *Der Onkologe.* 2021;27(9):858-61.
80. Emrich K, Kraywinkel K. Epidemiologie des Mammakarzinoms von Frauen: Trends in niedrigen Stadien. *Der Onkologe.* 2021;27(12):1156-64.
81. Erdmann F, Frederiksen LE, Bonaventure A, Mader L, Hasle H, Robison LL, Winther JF. Childhood cancer: Survival, treatment modalities, late effects and improvements over time. *Cancer Epidemiol.* 2021;71(Pt B):101733.
82. Fehr A, Werenicz S, Trocchi P, Falk M, Friedrich RE, Stammeler A, et al. Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping. *Virchows Archiv.* 2021;479(5):975-85.
83. Finke I, Behrens G, Maier W, Schwettmann L, Pritzkeleit R, Holleczeck B, et al. Small-area analysis on socioeconomic inequalities in cancer survival for 25 cancer sites in Germany. *Int J Cancer.* 2021;149(3):561-72.
84. Garbe C, Keim U, Gandini S, Amaral T, Katalinic A, Holleczeck B, et al. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. *Eur J Cancer.* 2021;152:18-25.
85. Gödde K, Siegerink B, Fügemann H, Keune D, Sander S, Schneider A, et al. Can routine register data be used to identify vulnerable lung cancer patients of suboptimal care in a German comprehensive cancer centre? *Eur J Cancer Care (Engl).* 2021;30(4):e13398.
86. González Maldonado S, Motsch E, Trotter A, Kauczor HU, Heussel CP, Hermann S, et al. Overdiagnosis in lung cancer screening: Estimates from the German Lung Cancer Screening Intervention Trial. *Int J Cancer.* 2021;148(5):1097-105.
87. Groeben C, Koch R, Kraywinkel K, Buttman-Schweiger N, Baunacke M, Borkowetz A, et al. Development of Incidence and Surgical Treatment of Penile Cancer in Germany from 2006 to 2016: Potential Implications for Future Management. *Annals of Surgical Oncology.* 2021;28(13):9190-8.

88. Guo F, Chen C, Holleczeck B, Schöttker B, Hoffmeister M, Brenner H. Strong Reduction of Colorectal Cancer Incidence and Mortality After Screening Colonoscopy: Prospective Cohort Study From Germany. *Am J Gastroenterol.* 2021;116(5):967-75.
89. Gurung-Schönfeld I, Kraywinkel K. Krebsregistrierung heute: zwischen Epidemiologie, Qualitätssicherung und Forschung. *Epidemiologisches Bulletin.* 2021;4:3-9.
90. Höhn AK, Klagges S, Gläser A, Taubenheim S, Dornhöfer N, Einenkel J, et al. Increase of fallopian tube and decrease of ovarian carcinoma: fact or fake? *J Cancer Res Clin Oncol.* 2021;147(3):911-25.
91. Jansen L, Kanbach J, Finke I, Arndt V, Emrich K, Holleczeck B, et al. Estimation of the Potentially Avoidable Excess Deaths Associated with Socioeconomic Inequalities in Cancer Survival in Germany. *Cancers (Basel).* 2021;13(2).
92. Jansen L, Moratin J, Waldmann A, Zaoui K, Holleczeck B, Nennecke A, et al. Mundhöhlen- und Pharynxkarzinome: Inzidenz, Mortalität und Überleben in Deutschland. *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.* 2021;64(8):941-50.
93. Jiang M, Fares AF, Shepshelovich D, Yang P, Christiani D, Zhang J, et al. The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. *Lung Cancer.* 2021;152:58-65.
94. Kappen S, de Bock GH, Sirri E, Vohmann C, Kieschke J, Winter A. Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing. *Front Oncol.* 2021;11:681006.
95. Liang LA, Einzmann T, Franzen A, Schwarzer K, Schaubberger G, Schriefer D, et al. Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotesting Strategies. *Cancer Epidemiol Biomarkers Prev.* 2021;30(3):474-84.
96. Liu Z, Doege D, Thong MSY, Koch-Gallenkamp L, Bertram H, Eberle A, et al. Distress mediates the relationship between cognitive appraisal of medical care and benefit finding/posttraumatic growth in long-term cancer survivors. *Cancer.* 2021;127(19):3680-90.
97. Liu Z, Thong MSY, Doege D, Koch-Gallenkamp L, Bertram H, Eberle A, et al. Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany. *Br J Cancer.* 2021;125(6):877-83.
98. Mahanani MR, Kaucher S, Kajüter H, Holleczeck B, Becher H, Winkler V. Colorectal Cancer among Resettlers from the Former Soviet Union and in the General German Population: Clinical and Pathological Characteristics and Trends. *International Journal of Environmental Research and Public Health.* 2021;18(9):4547.
99. Moser O, Zimmermann M, Meyer U, Klapper W, Oschlies I, Schrappe M, et al. Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group. *Haematologica.* 2021;106(5):1390-400.
100. Pruessmann J, Pursche T, Hammersen F, Katalinic A, Fischer D, Waldmann A. Conditional Disease-Free and Overall Survival of 1,858 Young Women with Non-Metastatic Breast Cancer and with Participation in a Post-Therapeutic Rehab Programme according to Clinical Subtypes. *Breast Care (Basel).* 2021;16(2):163-72.
101. Rudolph CES, Engholm G, Pritzkeleit R, Storm HH, Katalinic A. Survival of breast cancer patients in German-Danish border regions - A registry-based cohort study. *Cancer Epidemiol.* 2021;74:102001.
102. Sacchetto L, Rosso S, Comber H, Bouchardy C, Broganelli P, Galceran J, et al. Skin melanoma deaths within 1 or 3 years from diagnosis in Europe. *Int J Cancer.* 2021;148(12):2898-905.
103. Scherer-Trame S, Jansen L, Arndt V, Chang-Claude J, Hoffmeister M, Brenner H. Inpatient rehabilitation therapy among colorectal cancer patients - utilization and association with prognosis: a cohort study. *Acta Oncol.* 2021;60(8):1000-10.
104. Schoeps M, Effenberger M, Zeißig SR. Krebsregistrierung nichtmelanotischer Hauttumoren in Deutschland. *Der Onkologe.* 2021;27(6):525-31.

105. Schündeln MM, Lange T, Knoll M, Spix C, Brenner H, Bozorgmehr K, Stock C. Statistical methods for spatial cluster detection in childhood cancer incidence: A simulation study. *Cancer Epidemiol.* 2021;70:101873.
106. Schündeln MM, Lange T, Knoll M, Spix C, Brenner H, Bozorgmehr K, Stock C. Methods of spatial cluster detection in rare childhood cancers: Benchmarking data and results from a simulation study on nephroblastoma. *Data Brief.* 2021;34:106683.
107. Spoerl S, Gerken M, Mamilos A, Fischer R, Wolf S, Nieberle F, et al. Lymph node ratio as a predictor for outcome in oral squamous cell carcinoma: a multicenter population-based cohort study. *Clin Oral Investig.* 2021;25(4):1705-13.
108. Stangl S, Rauch S, Rauh J, Meyer M, Müller-Nordhorn J, Wildner M, et al. Disparities in accessibility to evidence-based breast cancer care facilities by rural and urban areas in Bavaria, Germany. *Cancer.* 2021;127(13):2319-32.
109. Wopen H, Rolf C, Braicu EI, Buttmann-Schweiger N, Barnes B, Baum J, et al. Secondary malignancies in long-term ovarian cancer survivors: results of the 'Carolin meets HANNA' study. *Int J Gynecol Cancer.* 2021;31(5):709-12.
110. Zeissig SR, Hamann R, Justenhoven C, al. e. Ovarialkarzinome - das Potenzial der Krebsregister - Analysen der Daten des Krebsregisters Rheinland-Pfalz zum Ovarialkarzinom im Vergleich zu Daten der QS-OVAR der AGO Studiengruppe. *Frauenarzt.* 2021;62(5):306-10.

2022

111. Alfaar AS, Saad A, Wiedemann P, Rehak M. The epidemiology of uveal melanoma in Germany: a nationwide report of incidence and survival between 2009 and 2015. *Graefes Arch Clin Exp Ophthalmol.* 2022;260(5):1723-31.
112. Alfaar AS, Suckert CN, Rehak M, Girbardt C. The epidemiology of adults' eyelid malignancies in Germany between 2009 and 2015; An analysis of 42,710 patients' data. *Eur J Ophthalmol.* 2022;33(2):11206721221125018.
113. Emrich K, Kraywinkel K. Epidemiologie des nichtkleinzelligen Lungenkarzinoms in Deutschland – ein Update. *Die Onkologie.* 2022;28(12):1038-42.
114. Feller A, Arndt V. Epidemiologie bösartiger Knochentumoren in Deutschland 2004–2018. *Die Onkologie.* 2022;28(7):551-4.
115. Jaehn P, Bergholz A, Holmberg C. Regional inequalities of tumour size at diagnosis in Germany: An ecological study in eight federal states. *Int J Cancer.* 2022;151(10):1684-95.
116. Jansen L, Feller A. Epidemiologie von Harnblasentumoren in Deutschland. *Die Onkologie.* 2022;28(9):737-41.
117. Kim-Wanner S-Z, Kraywinkel K. Faktenblatt: Epidemiologie der akuten Leukämien in Deutschland 2016 bis 2018. *Die Onkologie.* 2022;28(6):459-62.
118. Neuser P, Kraywinkel K, Kim-Wanner S-Z. Epidemiologie des Hodgkin-Lymphoms in Deutschland 2016 bis 2018. *Die Onkologie.* 2022;28(10):846-52.

2023

119. Abele M, Grabner L, Blessing T, Block A, Agaimy A, Kratz C, et al. Epidemiology and Characteristics of Gastric Carcinoma in Childhood—An Analysis of Data from Population-Based and Clinical Cancer Registries. *Cancers.* 2023;15(1):317.
120. Arndt V, Kraywinkel K. Factsheet Epidemiologie metastasierter Tumoren in Deutschland, 2015–2019: Inzidenz und 5-Jahres-Überleben. *Die Onkologie.* 2023;29(3):177-81.
121. Dahm S, Barnes B, Kraywinkel K. Detection of missed deaths in cancer registry data to reduce bias in long-term survival estimation. *Frontiers in Oncology.* 2023;13.
122. Dieckmann KP, Isbarn H, Trocchi P, Kießling M, Wülfing C, Stang A. No evidence for seasonal variations of the incidence of testicular germ cell tumours in Germany. *PLoS One.* 2023;18(5):e0286309.
123. Forner DM. Characteristics and survival of primary vaginal malignancy: an analysis of the German nationwide cancer registry data. *J Cancer Res Clin Oncol.* 2023;149(3):1115-22.

124. Gerber TS, Strobl S, Marx A, Roth W, Porubsky S. Epidemiology of Thymomas and Thymic Carcinomas in the United States and Germany, 1999-2019. 2023.
125. Herout R, Baunacke M, Flegar L, Borkowetz A, Reicherz A, Koch R, et al. Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019. *World J Urol.* 2023;41(1):127-33.
126. Jansen L, Schwettmann L, Behr C, Eberle A, Holleczeck B, Justenhoven C, et al. Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to 2018: An ecological registry-based study. *International Journal of Cancer.* 2023;n/a(n/a).
127. Liang LA, Tseng YJ, Tanaka LF, Klug SJ. Second primary cancer among 217702 colorectal cancer survivors: An analysis of national German cancer registry data. *Int J Cancer.* 2023.
128. Luttmann S, Eberle A, Hübner J. Epidemiologie der Adenokarzinome des Ösophagus und des ösophagogastralen Übergangs. *Die Onkologie.* 2023;29(6):470-8.
129. Neuser P, Kraywinkel K, Kim-Wanner S-Z. Faktenblatt: Epidemiologie der myeloproliferativen Neoplasien und des myelodysplastischen Syndroms in Deutschland 2017 bis 2019. *Die Onkologie.* 2023;29(4):281-6.
130. Schultz A, Kraywinkel K, Peters F. Faktenblatt: Epidemiologie des Endometriumkarzinoms in Deutschland 2009 bis 2019. *Die Onkologie.* 2023;29(5):391-5.
131. Tanaka LF, Figueroa SH, Popova V, Klug SJ, Buttman-Schweiger N. The Rising Incidence of Early-Onset Colorectal Cancer. *Dtsch Arztebl Int.* 2023;120:59-64.
132. Vahl JM, Nagel G, Grages A, Brand M, von Witzleben A, Sonntag M, et al. Demographics and access to head and neck cancer care in rural areas compared to urban areas in Germany. *Cancer Medicine.* 2023.